1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNA-Based Therapeutics and Vaccines Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 RNA-Based Therapeutics
1.2.3 RNA-Based Vaccines
1.3 Market by Application
1.3.1 Global RNA-Based Therapeutics and Vaccines Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Oncology
1.3.3 Immunology
1.3.4 Ophthalmology
1.3.5 Cardiovascular Diseases
1.3.6 Infectious Diseases
1.3.7 Genetic Diseases
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global RNA-Based Therapeutics and Vaccines Market Perspective (2018-2030)
2.2 RNA-Based Therapeutics and Vaccines Growth Trends by Region
2.2.1 RNA-Based Therapeutics and Vaccines Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 RNA-Based Therapeutics and Vaccines Historic Market Size by Region (2018-2023)
2.2.3 RNA-Based Therapeutics and Vaccines Forecasted Market Size by Region (2023-2030)
2.3 RNA-Based Therapeutics and Vaccines Market Dynamics
2.3.1 RNA-Based Therapeutics and Vaccines Industry Trends
2.3.2 RNA-Based Therapeutics and Vaccines Market Drivers
2.3.3 RNA-Based Therapeutics and Vaccines Market Challenges
2.3.4 RNA-Based Therapeutics and Vaccines Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue
3.1.1 Global Top RNA-Based Therapeutics and Vaccines Players by Revenue (2018-2023)
3.1.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Players (2018-2023)
3.2 Global RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA-Based Therapeutics and Vaccines Revenue
3.4 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio
3.4.1 Global RNA-Based Therapeutics and Vaccines Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA-Based Therapeutics and Vaccines Revenue in 2022
3.5 RNA-Based Therapeutics and Vaccines Key Players Head office and Area Served
3.6 Key Players RNA-Based Therapeutics and Vaccines Product Solution and Service
3.7 Date of Enter into RNA-Based Therapeutics and Vaccines Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA-Based Therapeutics and Vaccines Breakdown Data by Type
4.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Type (2018-2023)
4.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Type (2023-2030)
5 RNA-Based Therapeutics and Vaccines Breakdown Data by Application
5.1 Global RNA-Based Therapeutics and Vaccines Historic Market Size by Application (2018-2023)
5.2 Global RNA-Based Therapeutics and Vaccines Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
6.2 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
6.3 North America RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
7.2 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
7.3 Europe RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
8.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
8.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
9.2 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
9.3 Latin America RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size (2018-2030)
10.2 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2018-2023)
10.3 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Detail
11.1.2 Alnylam Pharmaceuticals Business Overview
11.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.1.4 Alnylam Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.1.5 Alnylam Pharmaceuticals Recent Development
11.2 Arbutus Biopharma
11.2.1 Arbutus Biopharma Company Detail
11.2.2 Arbutus Biopharma Business Overview
11.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Introduction
11.2.4 Arbutus Biopharma Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.2.5 Arbutus Biopharma Recent Development
11.3 Arrowhead Pharmaceuticals
11.3.1 Arrowhead Pharmaceuticals Company Detail
11.3.2 Arrowhead Pharmaceuticals Business Overview
11.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.3.4 Arrowhead Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.3.5 Arrowhead Pharmaceuticals Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech RNA-Based Therapeutics and Vaccines Introduction
11.4.4 BioNTech Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.4.5 BioNTech Recent Development
11.5 CureVac
11.5.1 CureVac Company Detail
11.5.2 CureVac Business Overview
11.5.3 CureVac RNA-Based Therapeutics and Vaccines Introduction
11.5.4 CureVac Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.5.5 CureVac Recent Development
11.6 Dicerna Pharmaceuticals
11.6.1 Dicerna Pharmaceuticals Company Detail
11.6.2 Dicerna Pharmaceuticals Business Overview
11.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.6.4 Dicerna Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.6.5 Dicerna Pharmaceuticals Recent Development
11.7 Regulus Therapeutics
11.7.1 Regulus Therapeutics Company Detail
11.7.2 Regulus Therapeutics Business Overview
11.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.7.4 Regulus Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.7.5 Regulus Therapeutics Recent Development
11.8 Marina Biotech
11.8.1 Marina Biotech Company Detail
11.8.2 Marina Biotech Business Overview
11.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Introduction
11.8.4 Marina Biotech Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.8.5 Marina Biotech Recent Development
11.9 MiRagen Therapeutics
11.9.1 MiRagen Therapeutics Company Detail
11.9.2 MiRagen Therapeutics Business Overview
11.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.9.4 MiRagen Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.9.5 MiRagen Therapeutics Recent Development
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Detail
11.10.2 Moderna Therapeutics Business Overview
11.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Introduction
11.10.4 Moderna Therapeutics Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.10.5 Moderna Therapeutics Recent Development
11.11 Quark Pharmaceuticals
11.11.1 Quark Pharmaceuticals Company Detail
11.11.2 Quark Pharmaceuticals Business Overview
11.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Introduction
11.11.4 Quark Pharmaceuticals Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.11.5 Quark Pharmaceuticals Recent Development
11.12 Roche
11.12.1 Roche Company Detail
11.12.2 Roche Business Overview
11.12.3 Roche RNA-Based Therapeutics and Vaccines Introduction
11.12.4 Roche Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.12.5 Roche Recent Development
11.13 Sylentis
11.13.1 Sylentis Company Detail
11.13.2 Sylentis Business Overview
11.13.3 Sylentis RNA-Based Therapeutics and Vaccines Introduction
11.13.4 Sylentis Revenue in RNA-Based Therapeutics and Vaccines Business (2018-2023)
11.13.5 Sylentis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
